AI carries security risks in banking, including being used by scammers to target financial information. Photo via Getty Images

With artificial intelligence technologies easily accessible and growing in popularity, consumers and business owners alike should be aware of both the benefits and risks when it comes to the utilization of generative AI tools in banking and finance. While data-driven AI creates the opportunity to further drive innovation in banking, the data-reliant nature of the industry makes it a natural target for scammers looking to intercept personal and business finances and sensitive customer information.

As banks and other financial service providers are using AI as a tool to scan for anomalies or errors that are known fraud techniques, criminals are using AI to improve their chances of perpetrating fraud. For this reason, consumers and businesses should guard their data with the same diligence used to guard cash and other valuable physical property.

Privacy and accuracy

For entrepreneurs and businesses of all sizes, it is important to keep in mind the practical applications of AI beyond the trending headlines, whether implementing the technology into everyday internal business practices, or into client-facing solutions.

When feeding information into AI, it is best to maintain a defensive position and be proactive about not disclosing sensitive or private information. Also, rely on sound judgment when deciding when and how to use AI technologies. From a business standpoint, privacy should be embedded into a financial system’s design and leaders should be transparent about the technologies used within a given system.

Technologies like ChatGPT are large language models operating on massive datasets, including documents and web pages across the internet. This poses a risk because some sources of this data lack accuracy. When seeking financial advice via AI technologies, it is best to conduct research by curating and limiting the dataset then talking through your unique financial position in person with your trusted banker and IT staff or consultants.

Phishing and business email compromise via AI

Historically, phishing and business email compromise, or BEC, attempts have been more easily recognizable and often flushed out due to grammatical errors and unnecessary punctuation. With technologies like ChatGPT, scammers are now better equipped to draft well written content that can fool a person into thinking a communication is legitimate. Phishing can lead to people clicking links or attachments that harbor malware or other viruses that can lead to account takeover. With BEC, a person might be fooled into thinking an email is from a legitimate person. Scams like these could potentially lead to the disclosing of sensitive information or accepting transaction instructions or changes, ultimately resulting in money being sent to a fraudster.

AI voice generators

AI voice generators can be used to mimic voices of anyone including bankers, C-suite leaders and customers. If a person is fooled into believing they have received a voicemail or are talking to a person they know, they may accept instructions from a fraudster like providing transaction approvals and sensitive or private information, resulting in fraud.

AI can also create fake identities, including AI-developed photos of individuals, and other false information. These fake identities could be used to create accounts for fraudulent purposes.

AI is here to stay

AI is forecasted to have a lasting impact on the banking industry. Whether on the business or consumer side of the spectrum, it will be important to embrace the innovation and enhancements generative AI will continue to produce, while maintaining a cautionary stance around protecting client and business information and finances. Fraud prevention practices will need to continue evolving alongside the fast-paced growth of generative AI in banking.

------

Ken Smiley is treasury management division manager of Amegy Bank and a fraud protection expert.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.